The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Orthopedic Use of BPC 157 Sports Med Review FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette FDA to weigh easing limits on peptides promoted by RFK Jr. NBC 6 South Florida Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions